Regulation of eosinophiI apoptosis: Transduction of survival and death signals

International Archives of Allergy and Immunology

Volumn 118, Issue 1, 1999, Pages 7-14

  Simon, Hans Uwe ^a   Alam, Rafeul ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Apoptosis; Eosinophils; Fas receptor; Inflammation; Interleukin 5; Nitric oxide; Signal transduction

Indexed keywords

CELL RECEPTOR; FAS ANTIGEN; PROTEIN TYROSINE KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN RECEPTOR; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC REACTION; APOPTOSIS; BONE MARROW; CELL ACTIVITY; CELL DEATH; CELL SURVIVAL; EOSINOPHIL; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE; ANIMAL; CHEMICAL STRUCTURE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL DEATH; CELL SURVIVAL; EOSINOPHILS; HUMANS; MODELS, MOLECULAR; NITRIC OXIDE; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032589733     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024025     Document Type: Review

References (62)

1. Bagley CJ, Lopez AF, Vadas MA: New frontiers for IL-5. J Allergy Clin Immunol 1997; 99:725-728.
2. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-3908.
3. Wedi B, Raap U, Lewrick H, Kapp A: Delayed eosinophil programmed cell death in vitro: A common feature of inhalant allergy and extrinsic and intrinsic dermatitis. J Allergy Clin Immunol 1997;100:536-543.
4. Woolley KL, Gibson PG, Carty K, Wilson AJ, Twaddell SH, Woolley MJ: Eosinophil apoptosis and its resolution of airway inflammation in asthma. Am J Respir Crit Care Med 1996;154: 237-243.
5. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS: Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995;86:1437-1443.
6. Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, Anderson GP, Coyle AJ: Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 1995;96:2924-2931.
7. Druilhe A, Cai Z, Hailé S, Chonaib S, Petrolani M: Fas-mediated apoptosis in cultured human eosinophils. Blood 1996;87:2822-2830.
8. Hebestreit H, Yousefi S, Balatti I, Weber M, Crameri R, Simon D, Hartung K, Schapowal A, Blaser K, Simon HU: Expression and function of the Fas receptor on human blood and tissue eosinophils. Eur J Immunol 1996;26: 1775-1780.
9. Green DR, Ware CF: Fas-ligand: Privilege and peril. Proc Natl Acad Sci USA 1997;94:5986-5990.
10. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R: The signal transduction mechanism of IL-5 in eosinophils: The involvement of lyn tyrosine kinase and the ras-raf I-MEK-MAP kinase pathway. J Exp Med 1995;181: 1827-1834.
11. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU: Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokine in human eosinophils. J Exp Med 1996;183:1407-1414.
12. Ogata N, Kuro T, Yamada A, Koike M, Hanai N, Ishikawa T, Takatsu K: Jak2 and Jak1 constitutively associated with an interleukin-5 (IL-5) receptor α and βc subunit, respectively, and are activated upon IL-5 stimulation. Blood 1998;91:2264-2271.
13. Pazdrak K, Stafford S, Alam R: The activation of the Jak-STAT1 signaling pathway by IL-5 in eosinophils. J Immunol 1995;155:397-402.
14. van der Bruggen T, Caldenhoven E, Kanters D, Coffer P, Raaijmakers JA, Lammers JW, Koenderman L: Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and STAT1α. Blood 1995;85:1442-1448.
15. Simon HU, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K: Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27:3536-3539.
16. Murakami M, Narazaki M, Hibi M, Yawata H, Yasukawa K, Hamaguchi M, Taga T, Kishimoto T: Critical region of the IL-6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 1991; 88:11349-11353.
17. Caldenhoven E, van Dijk T, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP: Activation of the STAT3/acute phase response factor transcription factor by interleukin-5. J Biol Chem 1995;270:25778-25784.
18. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A: IL-3, GM-CSF and IL-5 transduce signals through two Stat5 homologs. EMBO J 1995;14:1166-1175.
19. Coffer PJ, Schweizer RC, Dubois GR, Maikoe T, Lammers JW, Koenderman L: Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and T-helper 2-derived cytokines interleukin-4 and interleukin-5. Blood 1998;91:2547-2557.
20. Bates ME, Busse WW, Bertics PJ: Interleukin 5 signals through Shc and Grb2 in human eosinophils. Am J Respir Cell Mol Biol 1998; 18:75-83.
21. Pazdrak K, Adachi T, Alam R: SHPTP2/SHP2 tyrosine phosphatase is a positive regulator of the interleukin-5 receptor signal transduction pathways leading to the prolongation of eosinophil survival. J Exp Med 1997;186:561-568.
22. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo R, Alam R: Lyn, Jak2 and Raf-1 kinases are critical for the anti-apoptotic effect of interleukin-5. whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 1998;188:421-429.
23. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629-638.
24. L, in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92:778-783.
25. Alam R, Forsythe P, Stafford S, Fukuda Y: Transforming growth factor β abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994;179: 1041-1045.
26. Pazdrak K, Justement L, Alam R: Mechanism of inhibition of eosinophil activation by transforming growth factor-β. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. J Immunol 1995;155:4454-4458.
27. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
28. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349.
29. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G: Fas/APO-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol 1996;156:13-17.
30. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263: 1759-1762.
31. Simon HU, Yousefi S, Dommann-Scherrer CC, Zimmermann DR, Bauer S, Barandun J, Blaser K: Expansion of cytokine-producing T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183: 1071-1082.
32. Rothstein TL, Wang JKM, Panka DJ, Foote LC, Wang Z, Stanger B, Cui H, Ju ST. Marshak-Rothstein A: Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374:163-165.
33. Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL: IL-4 induces Fas resistance in B cells. J Immunol 1996;157:2749-2753.
34. Itoh N, Tsujimoto Y, Nagata S: Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993;151:621-627.
35. Boise LH, Thompson CB: Bcl-xL can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci USA 1997;94:3759-3764.
36. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-521.
37. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 1997;388: 190-195.
38. Lacana E, Ganjei JK, Vito P, D'Adamio L: Dissociation of apoptosis and activation of IL-1β-converting enzyme/Ced-3 proteases by ALG-2 and the truncated Alzheimer's gene ALG-3. J Immunol 1997;158:5129-5135.
39. Tatsuta T, Cheng J, Mountz JD: Intracellular IL-1β is an inhibitor of Fas-mediated apoptosis. J Immunol 1996;157:3949-3957.
40. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 1995;270:22625-22631.
41. Hebestreit H, Dibbert B, Balatti I, Braun D, Schapowal A, Blaser K, Simon HU: Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998;187:415-425.
42. Barnes PJ, Liew FY: Nitric oxide and asthmatic inflammation. Immunol Today 1995;16: 128-130.
43. Nagata S: Apoptosis by death factor. Cell 1997;88:355-365.
44. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
45. Eischen CM, Dick CJ, Leibson PJ: Tyrosine kinase activation provides an early and requisite signal for Fas-induced apoplosis. J Immunol 1994;153:1947-1954.
46. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R: Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. J Exp Med 1993;182:1545-1556.
47. Goillot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow E, Sanchez I: Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci USA 1997;94:3302-3307.
48. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnick R, Altman A, Green D: Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 1995;2:341-351.
49. Tepper CG, Jayadev S, Liu B, Bielwaska A, Wolff R, Yonehara S, Hannun YA, Seldin MF: Role of ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci USA 1995;92:8443-8447.
50. Haimovitz-Friedman A, Kan C, Ehleiter D, Persaud R, McLoghlin M, Fuks Z, Kolesnick RN: Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994;180:525-535.
51. Enari M, Talanian RV, Wong WW, Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-726.
52. Yang X, Khosravi-Far R, Chang HY, Baltimore D: Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89:1067-1076.
53. Latinis KM, Koretzky GA: Fas ligation induces apoptosis and Jun kinase activation independently of CD45 and Lck in human T cells. Blood 1996;87:871-875.
54. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD: Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 1995;2:353-362.
55. Sato T, Irie S, Kitada S, Reed JC: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-15.
56. Simon HU, Yousefi S, Dibbert B, Hebestreit H, Weber M, Branch DR, Blaser K, Levi-Schaffer F, Anderson GP: Role for tyrosine phosphorylation and Lyn tyrosine kinase in Fas receptor-mediated apoptosis in eosinophils. Blood 1998;92:547-557.
57. Gradl G, Grandison P, Lindridge E, Wang Y, Watson J, Rudert F: The CD95 (Fas/APO-1) receptor is phosphorylated in vitro and in vivo and constitutively associates with several cellular proteins. Apoptosis 1996;1:131-140.
58. Wang J, Koizumi T, Watanabe T: Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 1996;184:831-838.
59. Kolesnick R, Fuks Z: Ceramide: A signal for apoptosis or mitogenesis? J Exp Med 1995; 181:1949-1952.
60. Satoh T, Nakafuku M, Miyajima A, Kaziro Y: Involvement of ras p21 protein in signal transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin-4. Proc Natl Acad Sci USA 1991;88:3314-3318.
61. Gaudry M, Gilbert C, Barabé F, Poubelle PE, Naccache PH: Activation of Lyn is a common element of the stimulation of human neutrophils by soluble and particulate agonists. Blood 1995;86:3567-3574.
62. Clement MV, Stamenkovic I: Fas and tumor necrosis factor receptor-mediated cell death: Similarities and distinctions. J Exp Med 1994; 180:557-567.